Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Inclusion Criteria:

• At least 18 years old and has provided informed consent.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Histologically confirmed PDAC with successful (R0/R1) curative intent surgicalresection and no evidence of recurrent or metastatic disease.

• Must have received perioperative (neoadjuvant, adjuvant, or a combination of both)multi-agent chemotherapy.

• Must have completed most recent treatment within the past 12 weeks.

• Adequate organ function (bone marrow, liver, kidney, coagulation).

• Documented RAS mutation status.

• Able to take oral medications.

Exclusion Criteria:

• Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).

• Any conditions that may affect the ability to take or absorb study drug.

• Major surgery within 28 days prior to randomization.

• Patient is unable or unwilling to comply with protocol-required study visits orprocedures.